Clinical trials are expensive. Cardiocel will be running itself a profit by next year, and a successful HSV2 trial will be why we need the next CR. I can't see that being a negative to the share price. If HSV is not successful it stops a significant porportion of that burn.
Clinical trials are expensive. Cardiocel will be running itself...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
0.000(0.00%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.55 | 2592 | 2 |
View Market Depth
| Last trade - 16.14pm 23/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable